Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $15.18 and last traded at $15.18, with a volume of 167623 shares trading hands. The stock had previously closed at $15.84.
Analysts Set New Price Targets
Several research analysts have weighed in on KROS shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. HC Wainwright cut their price objective on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Scotiabank lowered their target price on Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a research note on Friday, December 13th. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Finally, Guggenheim cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, December 16th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $75.00.
Check Out Our Latest Analysis on KROS
Keros Therapeutics Trading Down 6.0 %
The stock's 50 day moving average price is $43.48 and its 200 day moving average price is $48.76. The company has a market capitalization of $603.15 million, a price-to-earnings ratio of -2.86 and a beta of 1.43.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the business earned ($1.33) earnings per share. The business's revenue was up 4750.0% on a year-over-year basis. On average, research analysts expect that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. boosted its position in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after purchasing an additional 577,220 shares during the period. Alkeon Capital Management LLC boosted its holdings in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after buying an additional 298,694 shares during the period. Parkman Healthcare Partners LLC grew its stake in Keros Therapeutics by 112.3% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock valued at $24,493,000 after buying an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock valued at $12,990,000 after buying an additional 199,245 shares during the last quarter. Finally, FMR LLC raised its holdings in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after acquiring an additional 179,374 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
